Castle Biosciences, Inc.
NASDAQ:CSTL
30.53 (USD) • At close September 19, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Revenue
| 219.788 | 137.039 | 94.085 | 62.649 | 51.865 | 22.786 | 13.754 |
| Cost of Revenue
| 55.554 | 32.009 | 15.822 | 9.685 | 7.31 | 5.297 | 4.922 |
| Gross Profit
| 164.234 | 105.03 | 78.263 | 52.964 | 44.555 | 17.489 | 8.832 |
| Gross Profit Ratio
| 0.747 | 0.766 | 0.832 | 0.845 | 0.859 | 0.768 | 0.642 |
| Reseach & Development Expenses
| 53.288 | 44.903 | 29.646 | 13.256 | 7.385 | 4.854 | 4.473 |
| General & Administrative Expenses
| 66.495 | 56.396 | 0 | 0 | 0 | 16.47 | 15.259 |
| Selling & Marketing Expenses
| 113.657 | 86.607 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 178.923 | 143.003 | 86.738 | 48.132 | 29.842 | 16.47 | 15.259 |
| Other Expenses
| 9.013 | 8.266 | 1.958 | -1.882 | -2.933 | -0.272 | 0.163 |
| Operating Expenses
| 232.211 | 196.172 | 118.342 | 59.506 | 37.227 | 21.325 | 19.732 |
| Operating Income
| -67.977 | -91.142 | -40.079 | -6.542 | 4.707 | -3.836 | -10.9 |
| Operating Income Ratio
| -0.309 | -0.665 | -0.426 | -0.104 | 0.091 | -0.168 | -0.792 |
| Total Other Income Expenses Net
| 10.612 | 22.238 | 0.067 | -3.658 | 0.642 | -0.272 | 0.163 |
| Income Before Tax
| -57.365 | -68.904 | -40.012 | -10.2 | 5.349 | -6.358 | -12.36 |
| Income Before Tax Ratio
| -0.261 | -0.503 | -0.425 | -0.163 | 0.103 | -0.279 | -0.899 |
| Income Tax Expense
| 0.101 | -1.766 | -8.72 | 0.084 | 0.072 | 0.009 | 0.01 |
| Net Income
| -57.466 | -67.138 | -31.292 | -10.284 | 5.277 | -6.367 | -12.37 |
| Net Income Ratio
| -0.261 | -0.49 | -0.333 | -0.164 | 0.102 | -0.279 | -0.899 |
| EPS
| -2.14 | -2.58 | -1.24 | -0.54 | 0.35 | -0.6 | -1.26 |
| EPS Diluted
| -2.14 | -2.58 | -1.24 | -0.54 | -0.21 | -0.6 | -1.26 |
| EBITDA
| -55.647 | -76.631 | -36.604 | -5.697 | 5.065 | -3.762 | -10.399 |
| EBITDA Ratio
| -0.253 | -0.559 | -0.389 | -0.091 | 0.098 | -0.165 | -0.756 |